Indications for: ENTYVIO
Moderately to severely active ulcerative colitis or Crohn’s disease.
Give by IV infusion over 30mins. ≥18yrs: 300mg at Weeks 0, 2, and 6, then every 8 weeks thereafter. Discontinue if no therapeutic benefit by Week 14.
<18yrs: not established.
Complete all immunizations according to current guidelines before initiating. Monitor for hypersensitivity reactions during and after infusion. Have epinephrine and antihistamines available. Discontinue if anaphylaxis or other serious infusion-related or hypersensitivity reactions occur. Active, severe infections: not recommended until controlled. Consider withholding if severe infection develops. History of recurring severe infections. Consider tuberculosis screening. Monitor for neurological signs/symptoms (those associated with progressive multifocal leukoencephalopathy [PML]); withhold dosing if suspected; permanently discontinue if confirmed. Discontinue if jaundice or significant liver injury occurs. Pregnancy. Nursing mothers.
Integrin receptor antagonist.
Avoid concomitant natalizumab, TNF blockers. Caution with concomitant live vaccines.
Nasopharyngitis, headache, arthralgia, nausea, pyrexia, upper respiratory tract infection, fatigue, cough, bronchitis, influenza, back pain, rash, pruritus, sinusitis, oropharyngeal pain, pain in extremities; infusion-related or hypersensitivity reactions, PML.
Register pregnant patients exposed to Entyvio by calling (877) 825-3327.
Generic Drug Availability:
Single-use vial (20mL)—1